新型冠状病毒肺炎治疗：采用基于网络的方法联合使用抗炎和抗病毒疗法。
COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach.
作者信息
Cheng Feixiong, Rao Sujata, Mehra Reena
机构信息
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH
Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH.
出版信息
Cleve Clin J Med. 2020 Jun 30. doi: 10.3949/ccjm.87a.ccc037.
To date, there are no effective antiviral medications for COVID-19. Drug repurposing, a strategy that uses existing drugs, offers potential prevention and treatment options for COVID-19. We discuss one treatment strategy that combines anti-inflammatory (melatonin) and antiviral (toremifene) agents for patients infected with SARS-CoV-2 from network medicine-based findings. We also describe the pathobiology and immunologic characteristics of COVID-19 and highlight the rationale of combination drug treatment to rescue the pulmonary and cardiovascular conditions resulting from COVID-19. A preliminary analysis reveals a high potential for the synergistic effects of melatonin and toremifene to reduce viral infection and replication, and the aberrant host inflammatory responses, offering strong biologic plausibility as an effective therapy for COVID-19.
迄今为止，尚无针对新冠病毒病的有效抗病毒药物。药物重新利用，即一种使用现有药物的策略，为新冠病毒病提供了潜在的预防和治疗选择。我们基于网络医学研究结果，探讨一种针对感染严重急性呼吸综合征冠状病毒2的患者联合使用抗炎药（褪黑素）和抗病毒药（托瑞米芬）的治疗策略。我们还描述了新冠病毒病的病理生物学和免疫学特征，并强调联合药物治疗对挽救新冠病毒病所致肺部和心血管疾病的基本原理。初步分析显示，褪黑素和托瑞米芬具有很高的协同效应潜力，可减少病毒感染和复制以及异常的宿主炎症反应，这为其作为新冠病毒病的有效疗法提供了强有力的生物学合理性。
Zotero 插件